Publication: Penicillium marneffei infection in immunocompromised host
Issued Date
2013-01-01
Resource Type
ISSN
1936377X
19363761
19363761
Other identifier(s)
2-s2.0-84873729610
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Current Fungal Infection Reports. Vol.7, No.1 (2013), 44-50
Suggested Citation
Maria Chitasombat, Khuanchai Supparatpinyo Penicillium marneffei infection in immunocompromised host. Current Fungal Infection Reports. Vol.7, No.1 (2013), 44-50. doi:10.1007/s12281-012-0119-5 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/32637
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Penicillium marneffei infection in immunocompromised host
Author(s)
Other Contributor(s)
Abstract
Penicillium marneffei (PM) was first described in 1973, causing human infection in a patient with Hodgkin Lymphoma. In the HIV/AIDS epidemic, it has been described as one of the important opportunistic infection following tuberculosis and cryptococcosis in endemic region of Southeast Asia and Southern China. Immunocompromised patients acquire penicilliosis through inhalation of conidia, resulting in disseminated disease characterized by prolonged fever, pancytopenia, hepatosplenomegaly, and classic cutaneous presentation of umbilicated papular eruption. Nowadays, rare manifestations such as fungemia, pneumonia, enterocolitis, genital ulcers, oral ulcer, and central nervous system infection have been reported. Over the past decade, molecular and genomic studies have revealed more knowledge of PM, and vaccines are under development. Modern era PM has become a serious threat in immunocompromised travelers, rather than HIV/AIDS patient in the endemic area, who receive an effective prophylaxis strategy along with the highly active antiretroviral therapy (HAART) initiation. © 2012 Springer Science+Business Media New York.